Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post-marketing study-Reference-Cited by-同舟云学术

Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post-marketing study

Published:2016-09-13 Issue:12 Volume:23 Page:1009-1015
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Katoh Takao¹,Kuwamoto Kana²,Kato Daisuke²,Kuroishi Kentarou²

Affiliation:

1. Cardiovascular Center; Mita Hospital; International University of Health and Welfare; Tokyo Japan

2. Astellas Pharma Inc; Tokyo Japan

Funder

Astellas Pharma US

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/iju.13218/fullpdf

Reference26 articles.

1. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society;Abrams;Urology,2003

2. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction;Irwin;BJU Int.,2011

3. Maximizing the treatment of overactive bladder in the elderly;Macdiarmid;Rev. Urol.,2008

4. Committee for Medicinal Products for Human Use (CHMP) Assessment report: Betmiga. European Medicines Agency 2012 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002388/WC500137308.pdf

5. An epidemiological survey of overactive bladder symptoms in Japan;Homma;BJU Int.,2005

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effects of Vibegron Add-on Therapy on Alpha 1-Blocker Therapy for Sexual Function and Overactive Bladder Symptoms in Benign Prostatic Hyperplasia: A Prospective, Open-Label Study;Journal of Clinical Medicine;2024-07-05

2. Analysis of urinary retention caused by selective β3-adrenoceptor agonists using the Japanese Adverse Drug Event Report database (JADER);PHARMAZIE;2023

3. Hong Kong Geriatrics Society and Hong Kong Urological Association consensus on personalised management of male lower urinary tract symptoms in the era of multiple co-morbidities and polypharmacy;Hong Kong Medical Journal;2021-04-21

4. Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity;International Urology and Nephrology;2021-01-08

5. Cardiovascular safety of mirabegron add‐on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study;LUTS: Lower Urinary Tract Symptoms;2020-09-25